Clinical trial
A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of…
NCT02133742 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT02133742 |
|---|---|
| Title | A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer |
| Official title | A PHASE 1B, OPEN LABEL, DOSE FINDING STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AXITINIB (AG-013736) IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH ADVANCED RENAL CELL CANCER |
| Lead sponsor | Pfizer, Industry |
| Collaborators | Merck Sharp & Dohme LLC Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | Axitinib, MK-3475 |
| Enrollment | 52 |
| Start date | Sep 16, 2014 |
| Primary completion | Mar 31, 2017 |
| Completion | Jul 3, 2019 |
| First posted | May 8, 2014 |
| Last update posted | Jul 28, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: